Rational use of oral H<sub>1</sub> receptor antagonists in children: a clinical practice guideline protocol_Chinese Journal of Evidence-Based Medicine

Authors：

ZHOU Pengxiang ^1,2 ,  ZHAI Suodi ^1,2 ,  ZHOU Wei ³

1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, P.R.China;
2. Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, P.R.China;
3. Department of Pediatrics, Peking University Third Hospital, Beijing 100191, P.R.China;

Corresponding?author：

ZHAI Suodi, Email: zhaisuodi@163.com; ZHOU Wei, Email: weiz6553@vip.sina.com

Keywords：

Oral H₁ receptor antagonists; Allergic disease; Children; Clinical practice guideline; Protocol

DOI：

10.7507/1672-2531.202009169

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The protocol of rational use of oral H₁ receptor antagonists in children: a clinical practice guideline primarily introduces key methods, processes and precautions of the guideline to standardize and guarantee the formulation of this evidence-based guideline. Referring to the World Health Organization Guidelines Development Manual, the guideline will be conducted according to the following steps, which involves the establishment of project group; registration (IPGRP-2020CN110); declaration of interest and funding support; identification of the clinical issues and outcomes; evidence retrieval, assessment, synthesis and utilization; investigation of patients’ preferences and values; development, external review and revision of recommendations; guideline release, dissemination and update.

Citation： ZHOU Pengxiang, ZHAI Suodi, ZHOU Wei. Rational use of oral H₁ receptor antagonists in children: a clinical practice guideline protocol. Chinese Journal of Evidence-Based Medicine, 2021, 21(1): 90-96. doi: 10.7507/1672-2531.202009169 Copy

1.	Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: world allergy organization statement. World Allergy Organ J, 2016, 9(1): 33.
2.	Stone KD. Advances in pediatric allergy. Curr Opin Pediatr, 2004, 16(5): 571-578.
3.	Wong GWK, Li J, Bao YX, et al. Pediatric allergy and immunology in China. Pediatr Allergy Immunol, 2018, 29(2): 127-132.
4.	向莉, 申昆玲. 兒童常見過敏性疾病診療概述. 中國醫學前沿雜志(電子版), 2013, (8): 1-5.
5.	Simons FE. Advances in H1-antihistamines. N Engl J Med, 2004, 351(21): 2203-2217.
6.	陳玉迪, 耿鵬, 涂平, 等. 抗組胺藥物在變態反應性疾病中的應用. 臨床藥物治療雜志, 2019, 17(1): 23-26.
7.	Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol, 2011, 128(6): 1139-1150.
8.	Caffarelli C, Paravati F, El HM, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr, 2019, 45(1): 101.
9.	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018, 73(7): 1393-1414.
10.	Bro?ek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol, 2017, 140(4): 950-958.
11.	Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg, 2015, 152(1 Suppl): S1-43.
12.	中國醫師協會兒科醫師分會兒童耳鼻咽喉專業委員會. 抗組胺藥治療嬰幼兒過敏性鼻炎的臨床應用專家共識. 中國實用兒科雜志, 2019, 34(9): 721-728.
13.	中華醫學會眼科學分會角膜病學組. 我國過敏性結膜炎診斷和治療專家共識(2018 年). 中華眼科雜志, 2018, 54(6): 409-414.
14.	Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 2016, 352: i1152.
15.	Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
16.	周鵬翔, 梁舒瑤, 翟所迪. 《兒科阿奇霉素注射使用的快速建議指南》實施方案介紹. 中國藥房, 2018, 29(4): 436-440.
17.	Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): National Academies Press (US), 2011.
18.	陳耀龍, 王健健, 詹思延, 等. 如何應對指南制訂中的利益沖突. 協和醫學雜志, 2019, 10(6): 685-691.
19.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
20.	Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 2015, 162(11): 777-784.
21.	von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 2007, 370(9596): 1453-1457.
22.	Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health, 2013, 16(2): e1-e5.
23.	Gagnier JJ, Kienle G, Altman DG, et al. The CARE Guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med, 2013, 2(5): 38-43.
24.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
25.	王明輝, 張菁, 曾憲濤, 等. 臨床實踐指南制訂方法—患者的價值觀和意愿. 中國循證心血管醫學雜志, 2018, 10(10): 1153-1156, 1161.
26.	Guyatt GH, Oxman AD, Kunz R, 等. GRADE: 從證據到推薦. 中國循證醫學雜志, 2009, 9(3): 257-259.
27.	陳耀龍, 荀楊芹, 李博, 等. 如何制訂患者指南. 協和醫學雜志, 2020, 11(4): 453-458.

1. Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: world allergy organization statement. World Allergy Organ J, 2016, 9(1): 33.
2. Stone KD. Advances in pediatric allergy. Curr Opin Pediatr, 2004, 16(5): 571-578.
3. Wong GWK, Li J, Bao YX, et al. Pediatric allergy and immunology in China. Pediatr Allergy Immunol, 2018, 29(2): 127-132.
4. 向莉, 申昆玲. 兒童常見過敏性疾病診療概述. 中國醫學前沿雜志(電子版), 2013, (8): 1-5.
5. Simons FE. Advances in H1-antihistamines. N Engl J Med, 2004, 351(21): 2203-2217.
6. 陳玉迪, 耿鵬, 涂平, 等. 抗組胺藥物在變態反應性疾病中的應用. 臨床藥物治療雜志, 2019, 17(1): 23-26.
7. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol, 2011, 128(6): 1139-1150.
8. Caffarelli C, Paravati F, El HM, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr, 2019, 45(1): 101.
9. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018, 73(7): 1393-1414.
10. Bro?ek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol, 2017, 140(4): 950-958.
11. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg, 2015, 152(1 Suppl): S1-43.
12. 中國醫師協會兒科醫師分會兒童耳鼻咽喉專業委員會. 抗組胺藥治療嬰幼兒過敏性鼻炎的臨床應用專家共識. 中國實用兒科雜志, 2019, 34(9): 721-728.
13. 中華醫學會眼科學分會角膜病學組. 我國過敏性結膜炎診斷和治療專家共識(2018 年). 中華眼科雜志, 2018, 54(6): 409-414.
14. Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 2016, 352: i1152.
15. Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
16. 周鵬翔, 梁舒瑤, 翟所迪. 《兒科阿奇霉素注射使用的快速建議指南》實施方案介紹. 中國藥房, 2018, 29(4): 436-440.
17. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): National Academies Press (US), 2011.
18. 陳耀龍, 王健健, 詹思延, 等. 如何應對指南制訂中的利益沖突. 協和醫學雜志, 2019, 10(6): 685-691.
19. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
20. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 2015, 162(11): 777-784.
21. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 2007, 370(9596): 1453-1457.
22. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health, 2013, 16(2): e1-e5.
23. Gagnier JJ, Kienle G, Altman DG, et al. The CARE Guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med, 2013, 2(5): 38-43.
24. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
25. 王明輝, 張菁, 曾憲濤, 等. 臨床實踐指南制訂方法—患者的價值觀和意愿. 中國循證心血管醫學雜志, 2018, 10(10): 1153-1156, 1161.
26. Guyatt GH, Oxman AD, Kunz R, 等. GRADE: 從證據到推薦. 中國循證醫學雜志, 2009, 9(3): 257-259.
27. 陳耀龍, 荀楊芹, 李博, 等. 如何制訂患者指南. 協和醫學雜志, 2020, 11(4): 453-458.

Chinese Journal of Evidence-Based Medicine

Rational use of oral H₁ receptor antagonists in children: a clinical practice guideline protocol

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Chinese Journal of Evidence-Based Medicine

Rational use of oral H1 receptor antagonists in children: a clinical practice guideline protocol

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Rational use of oral H₁ receptor antagonists in children: a clinical practice guideline protocol